ImmunityBio (IBRX)
(Delayed Data from NSDQ)
$3.52 USD
+0.04 (1.15%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $3.52 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth B Momentum F VGM
Income Statements
Fiscal Year end for ImmunityBio, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 1 | 0 | 1 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 1 | 0 | 1 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 363 | 352 | 331 | 92 | 68 |
Income After Depreciation & Amortization | -362 | -351 | -330 | -92 | -68 |
Non-Operating Income | -92 | -2 | -5 | -1 | 2 |
Interest Expense | 129 | 64 | 15 | 0 | 0 |
Pretax Income | -584 | -417 | -350 | -92 | -66 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | -1 | -1 | -3 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -584 | -417 | -350 | -92 | -66 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -583 | -417 | -347 | -92 | -66 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -301 | -315 | -316 | -82 | -59 |
Depreciation & Amortization (Cash Flow) | 61 | 36 | 14 | 10 | 9 |
Income After Depreciation & Amortization | -362 | -351 | -330 | -92 | -68 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 508.64 | NA | NA | NA | 94.21 |
Diluted EPS Before Non-Recurring Items | -0.99 | NA | NA | NA | -0.70 |
Diluted Net EPS (GAAP) | -1.15 | -1.04 | -0.89 | -0.89 | -0.70 |
Fiscal Year end for ImmunityBio, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 1.05 | 0.04 | 0.14 | 0.08 | 0.04 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 1.05 | 0.04 | 0.14 | 0.08 | 0.04 |
SG&A, R&D, and Dept/Amort Expenses | 100.38 | 95.24 | 85.53 | 80.22 | 85.19 |
Income After SG&A, R&D, and Dept/Amort Expenses | -99.33 | -95.20 | -85.39 | -80.14 | -85.15 |
Non-Operating Income | 3.77 | -1.45 | -115.94 | 19.52 | -20.83 |
Interest Expense | 39.02 | 37.49 | 32.13 | 35.02 | 32.24 |
Pretax Income | -134.58 | -134.13 | -233.45 | -95.64 | -138.21 |
Income Taxes | 0.00 | 0.00 | -0.04 | 0.00 | 0.00 |
Minority Interest | -0.02 | -0.02 | -0.02 | -0.06 | -0.33 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -134.58 | -134.13 | -233.41 | -95.64 | -138.21 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -134.56 | -134.11 | -233.39 | -95.58 | -137.88 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 686.94 | 672.83 | 617.80 | 498.38 | 437.46 |
Diluted EPS Before Non-Recurring Items | -0.20 | -0.20 | -0.19 | -0.19 | -0.28 |
Diluted Net EPS (GAAP) | -0.20 | -0.20 | -0.37 | -0.19 | -0.32 |